Intravenous CannulationNCT04164862
AccuVein AV400 Device Versus Ultrasound-guided Cannulation of the Great Saphenous Vein at the Ankle in Infants
A study testing AccuVein AV400 Device Versus Ultrasound-guided Cannulation in people with Intravenous Cannulation, run by Alexandria University at 1 site in Egypt.
Trial summary
Establishment of venousaccess in the age group ≤12 months can be difficult and associated with repetitive punctures . Numerous techniques to facilitate peripheral venous puncture have been described such as local warming, epidermal nitrogycerine, translumination, and venous cutdown . Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Intravenous Cannulation
- What is being tested?
- AccuVein AV400 Device Versus Ultrasound-guided Cannulation
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Sep 2019to Jan 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Infants' ≤12 months
- ASA physical status I and II
- undergoing elective surgery
- with no visible veins at the dorsum of the hands or feet
Who cannot join
- REFUSAL
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Effectiveness of AccuVein AV400 Device Versus Ultrasound-guided Cannulation of the Great Saphenous Vein at the Ankle in Infants: A Randomized Controlled Trial
Establishment of venousaccess in the age group ≤12 months can be difficult and associated with repetitive punctures . Numerous techniques to facilitate peripheral venous puncture have been described such as local warming, epidermal nitrogycerine, translumination, and venous cutdown . Ultrasound guidance is reported to facilitate peripheral venous catheterisation in children and to have advantages over blind techniques, especially for challenging veins . Also The AccuVein AV400 device which detects the haemoglobin in the vessels by red and infrared light reflection and shows a vasculature map. AccuVein AV400 device (AV400) improves the success rate of intravenous cannulation in pediatric patients .
Most peripheral veins in infants are too superficial and too small for direct visualization. A promising alternative approach could be the great saphenous vein (GSV) at the level of the medial malleolus due to the adequate diameter and the relatively deep position relative to the skin.
Read the detailed description
The present study is designed to investigate the practicability of ultrasound-guided vascular access versus the AccuVein AV 400 for cannulation of the great saphenous vein at the level of the medial malleoli in infants ≤12 months. The primary outcome will be the time to successful placement of catheters. Secondary outcomes included the number of attempts, the rate of failure, technique-related pain, occurrence of movements, and occurrence of complications like haematoma or local infection.
Patient and method:
A prospective, randomized study will be conducted from May 2019 till November 2019; at least 50 patients will be allocated in each group; at the Alexandria Main University Hospital after approval of the Medical Ethics Committee. Informed written consent will be obtained from the patient's parents. Infants' ≤12 months with ASA physical status I and II, undergoing elective surgery with no visible veins at the dorsum of the hands or feet will be enrolled in the study. Infants will be randomly assigned, by using a block of four randomization provided by www.randomization.com, into two groups; an AV400 group (using the AccuVein AV400 for peripheral venous insertion) and a ultrasound guided group (using the ultrasound for peripheral venous insertion). The performers of cannulation will be done by expert anesthetists, having a minimum of 5 times experience in ultra sound guided IV cannula insertion and with the AccuVein AV400 device.
Preoperatively in all infants, both medial malleolar areas will be prepared with EMLA cream , premedication with 1 mg/ kg rectal midazolam (maximum dose 15 mg) will be done at 30 minutes preoperative. Establishment of standard monitoring (SpO2, ECG, non-invasive arterial pressure) and then induction of general anaesthesia will be done via a face mask with sevoflurane FIO2 40% - O2/air and after successful induction of general anaesthesia, the EMLA tapes will be removed .Assisted ventilation via the face mask will be done until establishment of venous access either through using Acc Vein AV400 or through ultrasound guided for the great saphenous vein. On each occasion, the observer will record the time of tourniquet application, the time of successful cannulation or four skin punctures, and the number of cannulation attempts. A cannulation attempt will be defined as any backward and forward movements of the needle, regardless of whether the needle was out of the skin. Successful cannulation will be defined by the absence of tissue swelling around the puncture point after injection of 5 ml of crystalloid solution. In both groups, a maximal number of three attempts for establishment of venous access in one GSV will be performed. If the third attempt failed, the contralateral GSV will be punctured. If successful establishment of venous access in the contralateral GSV failed, the case will be counted as failure. In these cases, the external jugular vein will be used as an alternative approach for venous access. After successful establishment of venous access, the anaesthetic procedure will be continued depending on surgical requirements. Twenty-four hours after establishment of the venous access, the puncture site will be evaluated to detect possible haematoma or local infection.
- Conditions
- Intravenous Cannulation
- Being tested
- AccuVein AV400 Device Versus Ultrasound-guided Cannulation
- Keywords
- AccuVein AV400 device, ultrasound-guided cannulation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AccuVein AV400 Device Versus Ultrasound-guided CannulationDevice
Accuvein AV400 device versus Ultrasound guided cannulation
| Study group | Role | What they receive |
|---|---|---|
| use ACCUVEIN AV400 | Active comparator | Device to facilitate cannulation of the great saphenous vein at the ankle in infants Receives: Device: AccuVein AV400 Device Versus Ultrasound-guided Cannulation |
| ULTRASOUND GUIDED CANNULATION | Active comparator | Ultrasound cannulation of the great saphenous vein in infants Receives: Device: AccuVein AV400 Device Versus Ultrasound-guided Cannulation |
What is being measured
The primary outcome is the main question the study is designed to answer.
the time to successful placement of catheters
the time to successful placement of catheters
Measured: "Through operation completion, average of 2 hours"
Secondary outcomes (2)
the number of attempts
attempts for successful cannulation
Measured: "Through operation completion, average of 2 hours"
, technique-related pain, occurrence of movements, and occurrence of complications .
complications like haematoma or local infection.
Measured: "Through operation completion, average of 2 hours"
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Nov 2019
- Study start1 Sep 2019
- Primary completionDec 2019 (estimated)
- Study completionJan 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intravenous CannulationStudies of the same condition, open and under way.
- More trials run by Alexandria UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Alexandria University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, rehab zayed, Alexandria University
- Investigators
- Rehab Zayed, Ass.Prof., Principal investigator, Alexandria Universityyasser Osman, Ass. Prof., Principal investigator, Alexandria University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04164862
- Sponsor's protocol ID
- 00012098
- Other IDs
- 00018699
- Status last verified
- Nov 2019
- First submitted
- 5 Nov 2019
- Last updated
- 15 Nov 2019
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Nov 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of AccuVein AV400 Device Versus Ultrasound-guided Cannulation of the Great Saphenous Vein at the Ankle in Infants: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT04164862
- Acronym / sponsor ID
- 00012098
- Conditions
- Intravenous Cannulation
- Keywords
- AccuVein AV400 device, ultrasound-guided cannulation
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Alexandria UniversityUniversity, hospital or other
- Study start
- 1 Sep 2019 (actual)
- Primary completion
- Dec 2019 (estimated)
- Study completion
- Jan 2020 (estimated)
- First posted
- 15 Nov 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Establishment of venousaccess in the age group ≤12 months can be difficult and associated with repetitive punctures . Numerous techniques to facilitate peripheral venous puncture have been described such as local warming, epidermal nitrogycerine, translumination, and venous cutdown . Ultrasound guidance is reported to facilitate peripheral venous catheterisation in children and to have advantages over blind techniques, especially for challenging veins . Also The AccuVein AV400 device which detects the haemoglobin in the vessels by red and infrared light reflection and shows a vasculature map. AccuVein AV400 device (AV400) improves the success rate of intravenous cannulation in pediatric patients .
Most peripheral veins in infants are too superficial and too small for direct visualization. A promising alternative approach could be the great saphenous vein (GSV) at the level of the medial malleolus due to the adequate diameter and the relatively deep position relative to the skin.
Detailed description
The present study is designed to investigate the practicability of ultrasound-guided vascular access versus the AccuVein AV 400 for cannulation of the great saphenous vein at the level of the medial malleoli in infants ≤12 months. The primary outcome will be the time to successful placement of catheters. Secondary outcomes included the number of attempts, the rate of failure, technique-related pain, occurrence of movements, and occurrence of complications like haematoma or local infection.
Patient and method:
A prospective, randomized study will be conducted from May 2019 till November 2019; at least 50 patients will be allocated in each group; at the Alexandria Main University Hospital after approval of the Medical Ethics Committee. Informed written consent will be obtained from the patient's parents. Infants' ≤12 months with ASA physical status I and II, undergoing elective surgery with no visible veins at the dorsum of the hands or feet will be enrolled in the study. Infants will be randomly assigned, by using a block of four randomization provided by www.randomization.com, into two groups; an AV400 group (using the AccuVein AV400 for peripheral venous insertion) and a ultrasound guided group (using the ultrasound for peripheral venous insertion). The performers of cannulation will be done by expert anesthetists, having a minimum of 5 times experience in ultra sound guided IV cannula insertion and with the AccuVein AV400 device.
Preoperatively in all infants, both medial malleolar areas will be prepared with EMLA cream , premedication with 1 mg/ kg rectal midazolam (maximum dose 15 mg) will be done at 30 minutes preoperative. Establishment of standard monitoring (SpO2, ECG, non-invasive arterial pressure) and then induction of general anaesthesia will be done via a face mask with sevoflurane FIO2 40% - O2/air and after successful induction of general anaesthesia, the EMLA tapes will be removed .Assisted ventilation via the face mask will be done until establishment of venous access either through using Acc Vein AV400 or through ultrasound guided for the great saphenous vein. On each occasion, the observer will record the time of tourniquet application, the time of successful cannulation or four skin punctures, and the number of cannulation attempts. A cannulation attempt will be defined as any backward and forward movements of the needle, regardless of whether the needle was out of the skin. Successful cannulation will be defined by the absence of tissue swelling around the puncture point after injection of 5 ml of crystalloid solution. In both groups, a maximal number of three attempts for establishment of venous access in one GSV will be performed. If the third attempt failed, the contralateral GSV will be punctured. If successful establishment of venous access in the contralateral GSV failed, the case will be counted as failure. In these cases, the external jugular vein will be used as an alternative approach for venous access. After successful establishment of venous access, the anaesthetic procedure will be continued depending on surgical requirements. Twenty-four hours after establishment of the venous access, the puncture site will be evaluated to detect possible haematoma or local infection.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| use ACCUVEIN AV400 | Active comparator | Device: AccuVein AV400 Device Versus Ultrasound-guided CannulationDevice to facilitate cannulation of the great saphenous vein at the ankle in infants |
| ULTRASOUND GUIDED CANNULATION | Active comparator | Device: AccuVein AV400 Device Versus Ultrasound-guided CannulationUltrasound cannulation of the great saphenous vein in infants |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- Infants' ≤12 months
- ASA physical status I and II
- undergoing elective surgery
- with no visible veins at the dorsum of the hands or feet
Key exclusion criteria (1 listed)
- REFUSAL
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AccuVein AV400 Device Versus Ultrasound-guided CannulationAccuvein AV400 device versus Ultrasound guided cannulation | Device | ULTRASOUND GUIDED CANNULATION, use ACCUVEIN AV400 |
Primary outcome
the time to successful placement of catheters
Time frame: "Through operation completion, average of 2 hours"
the time to successful placement of catheters
2 secondary outcomes
the number of attempts
Time frame: "Through operation completion, average of 2 hours"
, technique-related pain, occurrence of movements, and occurrence of complications .
Time frame: "Through operation completion, average of 2 hours"
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Nov 2019.
Related trials for Intravenous Cannulation
Recruiting
Ultrasound-Guided Electrical Dry Needling for Chronic Cervical Radiculopathy
Cervical Radiculopathy
Enrolling by invitation
TruVascular Access - Ultrasound-Guided Vascular Access Study
Peripheral Venous Catheterization, Difficult Intravenous Access
Recruiting
Dry Needling in Multiple Sclerosis
Multiple Sclerosis
RecruitingObservational study
Frailty and Ultrasound-Guided Central Venous Catheterization Difficulty in Adult Cardiac Surgery Patients
Frailty, Cardiac Surgery
Not yet recruiting
Dry Needling and Quad Strength After Anterior Cruciate Ligament Reconstruction
Anterior Cruciate Ligament Reconstruction Rehabilitation, Dry Needling
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Rehab Zayed, Ass.Prof. principal investigator
Alexandria University
yasser Osman, Ass. Prof. principal investigator
Alexandria University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing AccuVein AV400 Device Versus Ultrasound-guided Cannulation in people with Intravenous Cannulation, run by Alexandria University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Nov 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
the time to successful placement of catheters (time frame: "Through operation completion, average of 2 hours"). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Nov 2019.